Advertisement

Search Results

Advertisement



Your search for Matthew Stenger matches 6096 pages

Showing 1 - 50


issues in oncology

Food Interventions and Cancer Treatment Completion Rates Among Food-Insecure Patients in New York City

In a study reported in the Journal of Clinical Oncology, Francesca Gany, MD, MS, and colleagues found that food interventions were associated with high rates of cancer treatment completion rates among food-insecure patients in New York City (NYC). Study Details The study included 117 patients with...

breast cancer

Screening Study to Identify Risk Factors for Breast Cancer–Related Lymphedema

In a prospective single-institution study reported in JAMA Oncology, Giacomo Montagna, MD, MPH, and colleagues found that the risk for breast cancer–related lymphedema after axillary lymph node dissection was increased in Black and Hispanic patients, those who received neoadjuvant chemotherapy, and ...

multiple myeloma

Association of CTC Levels With Outcomes in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma

In a study reported in the Journal of Clinical Oncology, Bertamini et al found that higher levels of circulating tumor cells (CTCs) at diagnosis were associated with poorer progression-free and overall survival in transplant-eligible patients with newly diagnosed multiple myeloma. The prognostic...

breast cancer

Study Seeks to Determine if HER2-Low Breast Cancer Is a Distinct Biological and Prognostic Subtype of Disease

The treatment of breast cancer abounding in the protein HER2 was revolutionized with the introduction of drugs like trastuzumab that target the protein. When researchers discovered that breast cancers with lower levels of HER2 often respond to a trastuzumab-and-chemotherapy drug conjugate, they...

pancreatic cancer
genomics/genetics

Outcomes in Pancreatic Cancer Surveillance Program for Carriers of Germline CDKN2A Pathogenic Variants

In a Dutch study reported in the Journal of Clinical Oncology, Klatte et al provided findings from a 20-year follow-up of a pancreatic cancer surveillance program including carriers of germline CDKN2A pathogenic variants. Study Details The study included 347 carriers in the Netherlands who...

lymphoma

Direct-Acting Antivirals in HCV-Associated Indolent Non-Hodgkin Lymphomas

As reported in the Journal of Clinical Oncology by Merli et al, the Fondazione Italiana Linfomi phase II BArT study has shown that primary treatment of hepatitis C virus (HCV)-associated indolent non-Hodgkin lymphomas with direct-acting antivirals resulted in sustained virologic response in all...

breast cancer

Fulvestrant/Capivasertib for Aromatase Inhibitor–Resistant Advanced Breast Cancer: Overall Survival and Expanded Genetic Panel Analysis From the FAKTION Trial

As reported in The Lancet Oncology by Howell et al, the phase II FAKTION trial has shown improved overall survival with the addition of the AKT inhibitor capivasertib to fulvestrant in patients with estrogen receptor–positive, HER2-negative advanced breast cancer who experienced disease relapse or...

gastroesophageal cancer
immunotherapy

Addition of Trastuzumab/Pertuzumab to Perioperative FLOT Chemotherapy in HER2-Positive Esophagogastric Adenocarcinoma

In the German phase II PETRARCA trial of the AIO EGA Study Group, reported in the Journal of Clinical Oncology, Hofheinz et al found that the addition of trastuzumab and pertuzumab to perioperative FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) improved both the pathologic complete...

prostate cancer

Is Focal Therapy With MRI-Guided Focused Ultrasound Safe and Effective for Grade Group 2 or 3 Prostate Cancer?

In a phase IIb study reported in The Lancet Oncology, Ehdaie et al found that focal ablation with magnetic resonance imaging (MRI)-guided focused ultrasound successfully treated a high proportion of patients with grade group 2 or 3 prostate cancer. As stated by the investigators, “Men with grade...

breast cancer

Risk of Interval Invasive and Advanced Breast Cancer: Screening With Digital Breast Tomosynthesis vs Digital Mammography

In a cohort study reported in JAMA, Karla Kerlikowske, MD, and colleagues found that screening with digital breast tomosynthesis (DBT) vs digital mammography was not associated with a lower risk of interval invasive breast cancer and was associated with a reduced risk of diagnosis of advanced...

breast cancer

Structural Racism and Health-Care System Barriers May Contribute to Breast Biopsy Delays

Black and Asian women are more likely than White women to experience significant delays in getting breast biopsies after a mammogram identifies an abnormality. Moreover, those delays appear to be influenced by screening site–specific factors that may stem from structural racism, according to...

head and neck cancer
immunotherapy

Role of Combined Positive Score With Treatment Outcomes in Recurrent or Metastatic Head and Neck Cancer

In an analysis of the KEYNOTE-048 trial reported in a research letter in JAMA Oncology, Yu et al identified outcomes with pembrolizumab alone or combined with chemotherapy vs cetuximab plus chemotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma with a low or...

leukemia
survivorship

Long-Term Morbidity in AML Survivors Treated With Blood or Bone Marrow Transplantation

As reported in the Journal of Clinical Oncology by Saro H. Armenian, DO, MPH, and colleagues, findings from the BMT Survivor Study (BMTSS) indicated that survivors of acute myeloid leukemia (AML) treated with blood or marrow transplantation (BMT) are at a markedly increased risk of...

thyroid cancer

AI May Be Used to Identify Benign Thyroid Nodules and Reduce Unnecessary Biopsies

Artificial intelligence (AI) may be used to identify thyroid nodules seen on thyroid ultrasound that are very unlikely to be cancerous, reducing a large number of unnecessary biopsies, according to a study presented at ENDO 2022, the Endocrine Society’s Annual Meeting. Thyroid nodules are very...

multiple myeloma

Circulating Tumor Cells in the Staging of Newly Diagnosed Patients With Transplant-Eligible Multiple Myeloma

In a study reported in the Journal of Clinical Oncology, Garcés et al found that increasing levels of circulating tumor cells (CTCs) at diagnosis were associated with poorer outcomes in newly diagnosed patients with transplant-eligible multiple myeloma, and that inclusion of CTCs in a risk model...

gastroesophageal cancer

Nivolumab in Combination With Chemotherapy and in Combination With Ipilimumab in Advanced Esophageal Squamous Cell Carcinoma

On May 27, 2022, nivolumab was approved for use in combination with fluoropyrimidine- and platinum-based chemotherapy and in combination with ipilimumab for the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma.1 Supporting Efficacy Data Approval was based on...

gynecologic cancers

ARIEL4 Trial: Rucaparib Improves Progression-Free Survival vs Chemotherapy in Relapsed Ovarian Cancer With BRCA1/2 Mutations

As reported in The Lancet Oncology by Rebecca Kristeleit, MD, of Guy’s and St. Thomas’ NHS Foundation Trust, and colleagues, the phase III ARIEL4 trial has shown a statistically significant improvement in progression-free survival with rucaparib vs chemotherapy in relapsed ovarian cancer with...

kidney cancer
immunotherapy

Nivolumab/Cabozantinib vs Sunitinib in First-Line Treatment for Advanced RCC: Overall Survival Analysis of CheckMate 9ER Trial

As reported in The Lancet Oncology by Robert J. Motzer, MD, and colleagues, the protocol-defined final overall survival analysis of the phase III CheckMate 9ER trial showed a significant benefit with nivolumab/cabozantinib vs sunitinib in previously untreated patients with advanced renal cell...

leukemia

Venetoclax Plus Cladribine and Low-Dose Cytarabine Alternating With Azacitidine and Venetoclax in Newly Diagnosed Older or Unfit Patients With AML

In a single-institution phase II study reported in the Journal of Clinical Oncology, Tapan M. Kadia, MD, and colleagues found that venetoclax and a lower-intensity backbone of cladribine and low-dose cytarabine alternating with azacitidine and venetoclax resulted in a high response rate in older...

pancreatic cancer

Outcomes of Pancreas Surveillance in the CAPS5 Study and Total CAPS Cohort

As reported in the Journal of Clinical Oncology by Dbouk et al, in the multicenter Cancer of Pancreas Screening-5 (CAPS5) study and in the total CAPS cohort (CAPS1–5 studies), cases of pancreatic ductal adenocarcinoma among enrolled high-risk individuals that were screen-detected during...

gynecologic cancers
genomics/genetics

Factors That May Predict Response to the Addition of Bevacizumab to Front-Line Chemotherapy in Patients With Endometrial Cancer

In an analysis from an NRG Oncology/Gynecologic Oncology Group phase II study (GOG-86P) reported in the Journal of Clinical Oncology, Thiel et al looked at outcomes in patients with advanced endometrial cancer treated with bevacizumab added to front-line chemotherapy. The investigators found that...

gynecologic cancers

Ovarian Cancer: First-Line Every-3-Week Carboplatin/Paclitaxel vs Weekly Dose-Dense Regimens

As reported in The Lancet Oncology by Andrew R. Clamp, PhD, and colleagues, no significant differences in overall survival or updated progression-free survival were found with first-line treatment with weekly dose-dense regimens of carboplatin/paclitaxel vs every-3-week carboplatin/paclitaxel in...

solid tumors

Does Receipt of Adjuvant Chemotherapy After Primary Retroperitoneal Lymph Node Dissection Affect Outcomes for Patients With Nonseminomatous Germ Cell Tumors?

In a single-institution study reported in the Journal of Clinical Oncology, Tachibana et al found high recurrence-free survival rates among patients with pathologic stage II nonseminomatous germ cell tumors who underwent primary retroperitoneal lymph node dissection and who did not receive adjuvant ...

colorectal cancer

Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer in Persons With HIV

In the phase III ANCHOR study reported in The New England Journal of Medicine, Palefsky et al found that treatment of high-grade squamous intraepithelial lesions was successful in preventing anal cancer vs active monitoring in persons infected with HIV. Study Details In the multicenter trial, 4,446 ...

prostate cancer

Cabozantinib and Atezolizumab for Patients With Progressive Metastatic Castration-Resistant Prostate Cancer Post–Hormonal Therapy

As reported in The Lancet Oncology by Neeraj Agarwal, MD, and colleagues, findings in the expansion cohort of the phase Ib COSMIC-021 trial indicate activity of the combination of cabozantinib and atezolizumab in patients with metastatic castration-resistant prostate cancer whose disease progressed ...

genomics/genetics

Germline Variants in Types of Cancer Without Hereditary Testing Guidelines

In a study reported in JAMA Network Open, Timothy A. Yap, MBBS, PhD, FRCP, and colleagues found that a substantial proportion of patients with cancer types that lacked hereditary testing guidelines harbored germline pathogenic/likely pathogenic variants. Study Details The study included data from...

pancreatic cancer

MMP-7 Expression and Pathologic Response to Neoadjuvant Treatment in Patients With Pancreatic Cancer Undergoing Resection

In a single-institution study reported in JAMA Surgery, Shoucair et al found that matrix metalloproteinase 7 (MMP-7) expression in fine-needle aspiration biopsy specimens was associated with pathologic response to neoadjuvant therapy in patients undergoing resection for pancreatic ductal...

colorectal cancer

Overall Survival in Patients With Metastatic Colorectal Cancer in Phase III Trials and SEER Database Over a 30-Year Period

In a study reported in JAMA Network Open, Shen et al found that data from both phase III trials and the Surveillance, Epidemiology, and End Results (SEER) database indicate significant improvements in overall survival for patients with metastatic colorectal cancer over a 30-year period. Increases...

immunotherapy
symptom management
multiple myeloma

Postmarketing Ocular Toxicity in U.S. Adults Treated With Daratumumab

In an analysis reported in a research letter in JAMA Oncology, Nguyen et al identified postmarketing cases of ocular toxicity in patients receiving daratumumab in the United States. Daratumumab is a CD38-directed monoclonal antibody that was initially approved in 2015 for the treatment of multiple...

leukemia

MRD-Guided Cessation of Treatment in Patients Receiving Venetoclax/Ibrutinib for Relapsed or Refractory CLL

In a phase II trial (HOVON141/VISION) reported in The Lancet Oncology, Arnon P. Kater, MD, PhD, and colleagues found a high rate of 12-month progression-free survival among patients with relapsed or refractory chronic lymphocytic leukemia (CLL) who stopped venetoclax/ibrutinib after achieving...

breast cancer

Can Abemaciclib Provide Good Clinical Outcomes in Patients With High-Risk Hormone Receptor–Positive, HER2-Negative Breast Cancer Who Received Neoadjuvant Chemotherapy?

In a prespecified analysis from the phase III monarchE trial reported in JAMA Oncology, Miguel Martín, MD, PhD, and colleagues found that the addition of adjuvant abemaciclib to endocrine therapy was associated with improved outcomes among women with high-risk hormone receptor–positive,...

lung cancer
immunotherapy

Real-World Association Between Smoking History and Overall Survival With First-Line Pembrolizumab in Patients With Advanced NSCLC

In a retrospective cohort study reported in JAMA Network Open, Sanjay Popat, FRCP, PhD, and colleagues found that among patients initiating first-line pembrolizumab for EGFR and ALK wild-type advanced non–small cell lung cancer (NSCLC), ever-smokers had significantly better overall survival vs...

colorectal cancer
immunotherapy

Addition of Atezolizumab to FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer

In an Italian phase II trial (AtezoTRIBE) reported in The Lancet Oncology, Antoniotti et al found that the addition of atezolizumab to FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, irinotecan) and bevacizumab improved progression-free survival in the first-line treatment of patients with...

lung cancer

Survival With Stereotactic Radiosurgery vs Whole-Brain Radiotherapy in Patients With SCLC and Intracranial Metastatic Disease

In a systematic review and meta-analysis reported in The Lancet Oncology, Gaebe et al found that stereotactic radiosurgery (SRS) was associated with “equitable survival” compared with whole-brain radiotherapy (WBRT) in the first-line treatment of intracranial metastatic disease in patients with...

genomics/genetics
myelodysplastic syndromes
leukemia

Demethylation and Upregulation of the Oncogene SALL4 After Hypomethylating Therapy

In a study reported in The New England Journal of Medicine, Liu et al found that hypomethylating therapy was associated with upregulation of the oncogene SALL4 in a high proportion of patients with myelodysplastic syndrome. They also identified the gene region that is demethylated and responsible...

prostate cancer

Potential Association of the 2012 USPSTF Grade D Recommendation Against PSA Screening With Changes in Prostate Cancer–Specific Mortality

In a study reported in JAMA Network Open, Burgess et al found that the 2012 U.S. Preventive Services Task Force (USPSTF) Grade D recommendation against prostate-specific antigen (PSA) screening for all men appeared to be associated with ending of a trend of annual reductions in prostate...

multiple myeloma

Proposed Second Revision of the International Staging System for Survival in Multiple Myeloma

As reported in the Journal of Clinical Oncology by D’Agostino et al in the European Myeloma Network, a second revision (R2-ISS) of the Revised International Staging System (R-ISS) incorporates a risk scoring system that permits delineation of four prognostic risk groups in newly diagnosed multiple...

breast cancer

Risk of Skin Desquamation With Breast Radiotherapy: Does Position Change Outcomes in Large-Breasted Women?

In a Canadian phase III trial reported in JAMA Oncology, Vesprini et al found that receipt of adjuvant breast radiotherapy in the supine position was associated with increased risk of moist desquamation of skin vs receipt in the prone position among large-breasted women with breast cancer. Study...

kidney cancer
immunotherapy

Longitudinal Liquid Biopsy for Circulating Tumor Cells in Metastatic Renal Cell Carcinoma

In a study reported in the Journal of Clinical Oncology, Bootsma et al found that higher circulating tumor cell (CTC) enumeration trajectory identified through longitudinal liquid biopsy was associated with poorer survival in patients receiving immune checkpoint inhibitor treatment for metastatic...

lung cancer

Intracranial Efficacy of Lorlatinib vs Crizotinib in ALK-Positive Advanced NSCLC

In a post hoc analysis from the phase III CROWN trial reported in the Journal of Clinical Oncology, Benjamin J. Solomon, MBBS, PhD, and colleagues found that progression-free survival and the risk of central nervous system (CNS) progression were improved with lorlatinib vs crizotinib in previously...

genomics/genetics
bladder cancer

Real-World Uptake of FGFR-Alteration Testing and Gene-Targeted Therapy for Patients With Urothelial Cancer

In a study reported in a research letter in JAMA Oncology, Nimgaonkar et al found that less than half of patients with urothelial cancer who had received first-line platinum-based therapy underwent testing for FGFR alterations and that less than half of patients with susceptible alterations...

breast cancer

Metformin vs Placebo in Patients With High-Risk Operable Breast Cancer Receiving Standard Treatment

As reported in JAMA by Pamela J. Goodwin, MD, MSc, FRCPC, FASCO, the phase III MA.32 trial showed no invasive disease–free survival benefit with metformin vs placebo in patients without diabetes receiving standard therapy for high-risk nonmetastatic breast cancer. Study Details In the double-blind ...

multiple myeloma
immunotherapy

MajesTEC-1: Bispecific Antibody Teclistamab for Relapsed or Refractory Multiple Myeloma

In the phase I/II MajesTEC-1 trial presented at the 2022 ASCO Annual Meeting (Abstract 8007) and simultaneously published in The New England Journal of Medicine, Philippe Moreau, MD, and colleagues found that the bispecific antibody teclistamab produced responses in nearly two-thirds of patients...

breast cancer

Personalized ctDNA Testing and Late Recurrence in High-Risk HR-Positive, HER2-Negative Breast Cancer

In a study presented at the 2022 ASCO Annual Meeting (Abstract 103) and simultaneously reported in the Journal of Clinical Oncology, Lipsyc-Sharf et al found that personalized circulating tumor DNA (ctDNA) testing was successful in detecting measurable residual disease (MRD) prior to late clinical...

prostate cancer
genomics/genetics

Differences in Germline Variant Spectrum Between Black and White Men With Prostate Cancer

In a study presented at the 2022 ASCO Annual Meeting (Abstract 10502) and simultaneously published in JCO Precision Oncology, Veda N. Giri, MD, and colleagues found that Black men with prostate cancer exhibited a lower frequency and narrower spectrum of germline pathogenic or likely pathogenic...

breast cancer
immunotherapy

Use of T-DXd in Previously Treated Patients With Advanced HER2-Positive Breast Cancer

On May 4, 2022, fam-trastuzumab deruxtecan-nxki (T-DXd) was granted regular approval for patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2–based regimen in the metastatic setting or in the neoadjuvant or adjuvant setting and have developed...

gynecologic cancers
immunotherapy

Cemiplimab-rwlc Improves Overall Survival vs Chemotherapy in Recurrent Cervical Cancer After First-Line Platinum-Based Chemotherapy

As reported in The New England Journal of Medicine by Krishnansu S. Tewari, MD, of the Division of Gynecologic Oncology, University of California, Irvine, and colleagues, the phase III ­EMPOWER-Cervical1/GOG-3016/ENGOT-cx9 trial has shown improved overall survival with cemiplimab-rwlc vs...

breast cancer
immunotherapy

T-DXd Improves Progression-Free Survival vs T-DM1 in Metastatic HER2-Positive Breast Cancer

As reported in The New England Journal of Medicine by Javier Cortés, MD, PhD, of the International Breast Cancer Center, Barcelona, and colleagues, the phase III DESTINY-Breast03 trial has shown significantly prolonged progression-free survival with fam-trastuzumab deruxtecan-nxki (T-DXd) vs...

multiple myeloma
immunotherapy

Ciltacabtagene Autoleucel in Relapsed or Refractory Multiple Myeloma: 2-Year Follow-up of CARTITUDE-1 Trial

In an analysis presented at the 2022 ASCO Annual Meeting (Abstract 8028) and simultaneously reported in the Journal of Clinical Oncology, Thomas Martin, MD, and colleagues provided data from the 2-year follow-up of the pivotal CARTITUDE-1 trial of the anti–B-cell maturation agent (BCMA) chimeric...

immunotherapy
symptom management

Incidence of Major Adverse Cardiac Events in Patients Receiving Immune Checkpoint Inhibitors

In a study presented at the 2022 ASCO Annual Meeting (Abstract 2508) and simultaneously reported in the Journal of Clinical Oncology, Naqash et al identified the incidence of major adverse cardiac events among patients receiving immune checkpoint inhibitors for cancer as captured in the serious...

Advertisement

Advertisement



Advertisement